[Biologic medications as second-line therapy for rheumatoid arthritis]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018002956
German
Original Title:
Biotechnologisch hergestellte Arzneimittel in der Zweitlinientherapie bei der rheumatoiden Arthritis
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a10-01.html
Year Published:
2013
URL for published report:
https://www.iqwig.de/download/A10-01_Abschlussbericht_Biologika-Zweitlinientherapie-bei-rheumatoider-Arthritis.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Arthritis, Rheumatoid
- Abatacept
- Adalimumab
- Certolizumab Pegol
- Etanercept
- Infliximab
- Interleukin 1 Receptor Antagonist Protein
- Rituximab
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Biological Products
Keywords
- Abatacept
- Adalimumab
- Anakinra
- Arthritis - Rheumatoid
- Benefit Assessment
- Certolizumab Pegol
- Etanercept
- Golimumab
- Infliximab
- Interleukin 1 Receptor Antagonist Protein
- Rituximab
- Systematic Review
- TNFR-Fc Fusion Protein
- Tocilizumab
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.